NAD+ raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-10-20 and is reviewed periodically as new material appears.
Terminology around NMN can be confusing because several related compounds share the vitamin B3 family. Nicotinamide riboside is a nucleoside, whereas NMN is a nucleotide with a phosphate group, and NAD+ is a dinucleotide coenzyme rather than a simple precursor. Niacin and nicotinamide are also NAD+ precursors but follow different metabolic entry points. In commercial and scientific writing, NMN usually refers to beta-nicotinamide mononucleotide unless another form is specified. Consistent nomenclature helps distinguish chemical identity from proposed biological effects.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a pyridine nucleotide that consists of a nicotinamide ring, a ribose sugar, and a phosphate group. It is an intermediate in the salvage pathway for nicotinamide adenine dinucleotide, or NAD+, synthesis. In mammalian cells, the enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. Nicotinamide mononucleotide adenylyltransferases then convert NMN into NAD+. The core structure and enzymatic route are well established in biochemical literature.
Research on NMN has expanded because NAD+ concentrations decline with age in some tissues and because NAD+ participates in energy metabolism, DNA repair, and signaling. Animal studies have reported changes in NAD+ levels after NMN administration, but human data are more limited and often focus on safety, pharmacokinetics, and biomarker changes. Questions remain about oral absorption, tissue distribution, and whether changes in blood NAD+ reflect changes inside specific organs. NMN is not an approved drug, and claims about its clinical effects should be distinguished from established biochemical findings.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide ring, a ribose sugar, and a phosphate group. The compound exists in cells as an intermediate in the production of nicotinamide adenine dinucleotide, a central redox cofactor. NMN is distinct from nicotinamide riboside, another related pyridine nucleotide, although the two compounds can converge in metabolic pathways. Its chemical formula is C11H15N2O8P, and it carries a net negative charge at physiological pH.
In the salvage pathway, NMN is generated from nicotinamide and 5-phosphoribosyl-1-pyrophosphate by the enzyme nicotinamide phosphoribosyltransferase. A second route produces NMN from nicotinamide riboside through phosphorylation by nicotinamide riboside kinases. NMN is then converted to NAD+ by nicotinamide mononucleotide adenylyltransferases, often called NMNAT enzymes. This stepwise route allows cells to recycle nicotinamide and maintain NAD+ levels under changing metabolic conditions. The relative contribution of each route varies by tissue, species, and physiological state, and it remains an active area of research.
| Property | Value | Notes |
|---|---|---|
| Systematic class | Pyridine nucleotide | Contains nicotinamide, ribose, and phosphate |
| Common form | beta-NMN | Anomeric configuration relevant to enzyme recognition |
| Molecular formula | C11H15N2O8P | As the free acid |
| Molar mass | 334.22 g/mol | Calculated for the free acid |
| CAS Registry Number | 1094-61-7 | Commonly associated with beta-D-NMN |
In the canonical salvage pathway, nicotinamide phosphoribosyltransferase, known as NAMPT, transfers a phosphoribosyl group to nicotinamide and releases NMN. A second enzyme, NMN adenylyltransferase, then attaches an adenylyl group to NMN to form NAD+. Alternative routes exist, including a pathway that uses nicotinamide riboside and its phosphorylated forms. The relative contribution of extracellular NMN to intracellular NAD+ pools remains an area of active investigation, and the roles of specific transporters and enzymes are not completely defined.
NMN is present in small amounts in various foods, including certain vegetables, fruits, and milk, though dietary quantities are generally low. Laboratory research often uses synthetic or enzymatically produced NMN. The compound has drawn interest because NAD+ levels decline with age in some tissues and because restoring NAD+ may affect metabolism in animal models. Whether oral NMN produces meaningful NAD+ increases in humans and whether such changes translate into health benefits are not fully established.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide base with a ribose sugar and a phosphate group. Within cells, NMN sits on the biosynthetic route that recycles nicotinamide back into nicotinamide adenine dinucleotide, or NAD+. Because NAD+ participates in redox reactions and signaling, enzymes that produce and consume it influence many metabolic processes. The compound is therefore best described as an intermediate rather than a final signaling molecule.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide found in cells. Its structure consists of a nicotinamide ring linked to ribose phosphate, and the compound serves as an intermediate in the salvage pathway for nicotinamide adenine dinucleotide, or NAD+. In this pathway, nicotinamide phosphoribosyltransferase converts nicotinamide and phosphoribosyl pyrophosphate into NMN, after which NMN adenylyltransferase attaches an adenylate group to produce NAD+. Because NAD+ participates in redox reactions and signaling, NMN occupies a central position in cellular metabolism. The molecule is distinct from nicotinamide riboside, though the two are related in NAD+ precursor research.
Beyond its intracellular synthesis, NMN can be taken up from the extracellular environment, although the routes are still debated. Some evidence points to direct transport into cells through specific transporters, while other work suggests dephosphorylation to nicotinamide riboside followed by cellular uptake. Once inside, NMN can be converted to NAD+ by NMN adenylyltransferases; the relative contribution of these routes may differ by tissue, species, and experimental conditions. Researchers continue to investigate which mechanisms dominate in intact organisms and how they affect measured NAD+ levels. Direct measurement in tissues remains technically challenging because NMN can be rapidly metabolized during sample collection.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide. Its structure consists of a nicotinamide ring attached to a ribose sugar that carries a phosphate group. The molecular formula is C11H15N2O8P, and the molar mass is about 334.22 grams per mole. In cells, NMN is an intermediate in the salvage pathway that recycles nicotinamide to maintain NAD+ levels. It is not the same compound as NAD+, although it is a direct precursor in one enzymatic step.
Inside cells, the enzyme nicotinamide phosphoribosyltransferase, or NAMPT, converts nicotinamide and a ribose-phosphate donor into NMN. A second enzyme, NMN adenylyltransferase, then converts NMN into NAD+. NAD+ participates in redox reactions and serves as a substrate for signaling enzymes such as sirtuins, PARPs, and CD38. Because NAD+ levels tend to decline with age in many organisms, NMN has drawn interest as a possible way to influence that decline. Whether oral NMN reliably raises NAD+ in human tissues, and whether any such change modifies disease risk, remain open research questions.
NMN is present in small amounts in some foods, including certain vegetables, fruits, and animal products, but food content varies widely and is not well standardized. In laboratory research, NMN is used as a tool compound to study NAD+ metabolism, mitochondrial function, and cellular stress responses. Animal studies have reported changes in NAD+ levels and various physiological measures after NMN administration, but species differences and study designs limit direct extrapolation to humans. Human trials have largely focused on safety, tolerability, and pharmacokinetics, with fewer studies examining clinical endpoints.
The presence of bulky ligands can also increase the rate of elimination. Ligands such as phosphines with large bite angles cause steric repulsion between L and R1 and R2, resulting in the angle between L and the R groups to increase and the angle between R1 and R2 to hence decrease, allowing for quicker reductive elimination.
A presentation seen during gameplay reveals that GLaDOS was included in a proposed bid for de-icing fuel lines, incorporated as a fully functional disk-operation system that is arguably alive, unlike Black Mesa's proposal, which inhibits ice, nothing more. After contracting a terminal illness from moon rocks used in portal experiments, Cave decides to attempt to back up his consciousness to a computer. He realises that the technology will not be ready in time to backup his brain due to his imminent demise, and leaves instructions to forcefully backup the consciousness of his assistant Caroline. Upon being uploaded to GLaDOS, Caroline attempts to kill every scientist in the building in under a fraction of a second. After extensive attempts to control her with smaller robots called personality spheres that would act as emotional limits and a sort of artificial "conscience", GLaDOS managed to eventually convince the scientists that she was primarily concerned with science and requested a lethal brain neurotoxin for an experiment about cats. GLaDOS initiated the experiment during the company's first annual bring-your-daughter-to-work day in 1998. Immediately after activation, the facility was flooded with deadly neurotoxin by the AI. Events of the first Half-Life game occur shortly after that, presumably leaving the facility forgotten by the outside world due to apocalyptic happenings. Wolpaw, in describing the ending of Portal 2, affirmed that the Combine invasion, chronologically taking place after Half-Life and before Half-Life 2, had occurred before Portal 2's events.
=== 2020 sesame seeds contamination === In September 2020, high levels of pesticides were found in 268 tonnes of sesame seeds from India. The contamination had a level of 1000 to 3500 times the limit of 0.05 milligrams per kilogram for ethylene oxide allowed in Europe. This pesticide is forbidden in Europe, where it is recognized to be carcinogenic and mutagenic. A product recall was made, half of the products had an organic certification. In September, alert was raised by Belgium by RASFF, but the product has also been sold in other EU single market countries such as France and Ireland.
She has written two volumes of autobiography, This Much is True (2021) and Oh Miriam! (2023). Leo Marks, cryptographer and screenwriter Madeleine Masson Rayner (née Levy; 23 April 1912 – 23 August 2007), author of plays, film scripts, novels, memoirs and biographies; best known for her biography of the highly respected and decorated war heroine, Polish agent of the British Special Operations Executive, Krystyna Skarbek. Roy Masters (commentator) (born 2 April 1928, died 22 April 2021); English-born American author of over twenty self-help pop psychology books, radio personality, businessman and hypnotist. Anna Maxted, novelist and journalist. She is former Assistant Editor of Cosmopolitan, and has freelanced for most national newspapers and magazines, including The Independent on Sunday, The Daily Telegraph, The Daily Mirror, Sunday Mirror, The Times, Daily Express, FHM, Esquire and Living Etc. Mark Mazower (born 20 February 1958) historian, scholar, academic and author of over fifteen books, largely on fascism, Greece, the Balkans and 20th-century Europe; of Russian Jewish descent; has also written for the Financial Times and for The Independent; has been appointed to the Advisory Board of the European Association of History Educators (EUROCLIO) and is member of the Editorial Board for Past & Present.
=== Prenatal development === The prenatal portion of tissue-resident dermal macrophages is produced from yolk-sac derived precursors. The generation of dermal macrophages results from primitive haematopoiesis or definitive haematopoiesis. Primitive haematopoiesis allows the generation of yolk-sac derived macrophages and subsequent release into the foetal bloodstream for tissue infiltration and colonisation. The infiltration of the skin by yolk-sac derived macrophages occurs as soon as 8.5 days after fertilisation. Different gene expressions regulate this process. It is independent of the MYB gene and dependent on the PU.1 gene. Definitive haematopoiesis occurs from 11 days and onwards after fertilisation. Monocytes are produced from haematopoietic stem cells in the liver, and they subsequently infiltrate the skin via the foetal bloodstream. In this process, cytokines like CSF1 are essential in facilitating the differentiation of monocytes into tissue-resident dermal macrophages and their survival. Therefore, the differentiation of monocytes to dermal macrophages is CSF-1/CSF1R dependent. The level of dermal macrophages from prenatal development remains detectible through constant, slow proliferation.
Sources: en.wikipedia.org
SASP induces an unfolded protein response in the endoplasmic reticulum because of an accumulation of unfolded proteins, resulting in proteotoxic impairment of cell function. SASP cytokines can result in an inflamed stem cell niche, leading to stem cell exhaustion and impaired stem cell function. The pro-inflammatory environment generated by SASP factors accelerates the breakdown of extracellular matrix thereby worsening intervertebral disc degeneration (IVDD). AMPK/p53 senescence produces a completely different SASP than IL-1 (p16INK4a) senescence, which is primarily responsible for IVDD. In IVDD, SASP is secreted by nucleus pulposus and annulus fibrosus cells, resulting in extracellular matrix degradation and extracellular inflammation. Senomorphics, but not senolytics have been found to alleviate symptoms without eliminating senescent cells. SASP can either promote or inhibit cancer, depending on the SASP composition, notably including p53 status. Despite the fact that cellular senescence likely evolved as a means of protecting against cancer early in life, SASP promotes the development of late-life cancers. Cancer invasiveness is promoted primarily through the actions of the SASP factors metalloproteinase, chemokine, interleukin 6 (IL-6), and interleukin 8 (IL-8). In fact, SASP from senescent cells is associated with many aging-associated diseases, including not only cancer, but atherosclerosis and osteoarthritis. For this reason, senolytic therapy has been proposed as a generalized treatment for these and many other diseases.
== Bibliography == Cooper, Reginald R.; Milgram, James W.; Robinson, Robert A. (1966). "Morphology of the Osteon: An Electron Microscopic Study". Journal of Bone and Joint Surgery. 48 (7): 1239–1271. doi:10.2106/00004623-196648070-00001. PMID 5921783. Netter, Frank H. (1987), Musculature system: anatomy, physiology, and metabolic disorders. Summit, New Jersey: Chiba-Geiger Corporation ISBN 0-914168-88-6
In 2014, when Russia-United States and Russia-NATO relations worsened over the Annexation of Crimea, the Russian state-owned television channel Russia 1 stated that "Russia is the only country in the world that is really capable of turning the USA into radioactive ash." U.S. Secretary of Defense Ash Carter considered proposing deployment of ground-launched cruise missiles in Europe that could pre-emptively destroy Russian weapons. In August 2017, North Korea warned that it might launch mid-range ballistic missiles into waters within 18 to 24 miles (29 to 39 km) of Guam, following an exchange of threats between the governments of North Korea and the United States. Escalating tensions between North Korea and the United States, including threats by both countries that they could use nuclear weapons against one another, prompted a heightened state of readiness in Hawaii. The perceived ballistic missile threat broadcast all over Hawaii on 13 January 2018 was a false missile alarm. In October 2018, the former Soviet leader Mikhail Gorbachev commented that U.S. withdrawal from the Intermediate-Range Nuclear Forces Treaty is "not the work of a great mind" and that "a new arms race has been announced". In early 2019, more than 90% of world's 13,865 nuclear weapons were owned by Russia and the United States. In 2019, Vladimir Putin warned that Russia would deploy nuclear missiles in Europe if the United States deployed intermediate-range nuclear missiles there.
=== Major neuroendocrine axes === Oxytocin and vasopressin (also called anti-diuretic hormone), the two neurohypophysial hormones of the posterior pituitary gland (the neurohypophysis), are secreted from the nerve endings of magnocellular neurosecretory cells into the systemic circulation. The cell bodies of the oxytocin and vasopressin neurons are in the paraventricular nucleus and supraoptic nucleus of the hypothalamus, respectively, and the electrical activity of these neurons is regulated by afferent synaptic inputs from other brain regions. By contrast, the hormones of the anterior pituitary gland (the adenohypophysis) are secreted from endocrine cells that, in mammals, are not directly innervated, yet the secretion of these hormones (adrenocorticotrophic hormone, luteinizing hormone, follicle-stimulating hormone, thyroid-stimulating hormone, prolactin, and growth hormone) remains under the control of the hypothalamus. The hypothalamus controls the anterior pituitary gland via releasing factors and release-inhibiting factors; these are substances released by hypothalamic neurons into blood vessels at the base of the brain, at the median eminence. These vessels, the hypothalamo-hypophysial portal vessels, carry the hypothalamic factors to the anterior pituitary, where they bind to specific receptors on the surface of the hormone-producing cells. For example, the secretion of growth hormone is controlled by two neuroendocrine systems: the growth hormone-releasing hormone (GHRH) neurons and the somatostatin neurons, which stimulate and inhibit GH secretion, respectively.
Sources: en.wikipedia.org
NMN stands for nicotinamide mononucleotide. It is a naturally occurring nucleotide intermediate in NAD+ biosynthesis.
NMN is a direct precursor in the salvage pathway that produces NAD+. Enzymes called NMN adenylyltransferases convert NMN into NAD+, a coenzyme involved in redox reactions and signaling.
No. Nicotinamide riboside is a related compound that lacks the phosphate group present in NMN. Both can influence NAD+ pathways, but their structures, transport, and metabolism differ.
NMN stands for nicotinamide mononucleotide. It is a naturally occurring nucleotide and an intermediate in the cellular production of NAD+.